Build status - In Progress

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)

Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome (AEGIS-II)
Recruiting
18 years - 99 years
All
Phase 3
1000 participants needed
1 Location

Brief description of study

This is a multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events (MACE) in subjects with Acute Coronary Syndrome (diagnosed with STEMI or NSTEMI), who are receiving evidence-based medical therapy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Acute Coronary Syndrome
  • Age: 18 years - 99 years
  • Gender: All

Male or Female, Age 18 or older, Evidence of myocardial necrosis, consistent with type I (spontaneous) MI

Updated on 04 Aug 2024. Study ID: 829891

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center